Cigna management check

CI · Health Care · Health Care Services · CEO David M. Cordani

Filings as of

80
Management score, ranked 60th of 487 · 6th of 60 in Health Care4 good · 2 to watch · 0 flaggedStrongest: dilution · Weakest: owner returns · Best and worst run in Health Care →

Closest peers in Health Care Services

  1. 50VRTXVertex Pharmaceuticals81
  2. 60CICigna80
  3. 126DVADaVita74
  4. 218DGXQuest Diagnostics67
  5. 223LHLabcorp66
  6. 305CVSCVS Health61

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$145Peers$148

    What $100 became since fiscal 2021

    4752nd
    Detail

    $100 invested at the start of fiscal 2021 grew to $145, against $148 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    7841st
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.55 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.4% of net income

    $22.9m pay · $6.0bn net income, FY2025

    0.1%1%3%10%
    8583rd
    Detail

    $22.9m of reported pay in fiscal 2025, against $6.0bn of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing
    ——

    Light activity: no buys, $6.6m sold in six months. 3 of 4 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 341m2025 · 269m

    Diluted shares −4.9% a year; flagged above +2%

    0%10%20%

    Stock pay 0.1% of revenue

    100100th
    Detail

    Diluted shares changed -4.9% a year over the last three fiscal years. Stock-based pay was 0.1% of revenue in the latest year.

  • Watch

    Is leadership stable?

    11 leadership filings in 3 years

    11 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: David M. Cordani

    7046th
    Detail

    CEO in the pay table: David M. Cordani. 11 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 13, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$28.7m$57.4m$10020212022202320242025$145$148

Pay tied most to adjusted income from operations, per share

Other key measuresAdjusted Income from OperationsAdjusted Income from Operations, per ShareAdjusted RevenuesCustomer & Patient SatisfactionGrowth in Specialty Pharmacy PrescriptionsEmployee EngagementRelative Total Shareholder Return

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025David M. Cordani$22.9m$14.6m$6.9m$145$148$6.0bn
2024—$23.3m$18.9m$8.1m$142$129$3.4bn
2023—$21.0m$8.1m$6.8m$152$126$5.2bn
2022—$21.0m$57.4m$6.3m$165$124$6.7bn
2021—$19.9m$15.4m$7.2m$112$126$5.4bn

Insiders and the CEO's stakeQuiet

Light activity: no buys, $6.6m sold in six months. 3 of 4 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldNicole S JonesSee Remarks · 10b5-1 plan$6.1mAug 18, 2026
  • SoldJamie G KatesChief Accounting Officer$268kJun 12, 2026
  • SoldEverett NevilleSee Remarks · 10b5-1 plan$175kSep 3, 2026

Leadership and governance on file

20222023202420252026Leadership 13Votes 5
All 13 filings

Latest shareholder vote results: Apr 27, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $35.6bn returned to owners in buybacks and dividends, 245% of net income, and $1.4bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$4.5bn$9.1bn20212022202320242025Shares341m313m297m283m269m
Show the figures
Fiscal year20212022202320242025
Revenue$174.1bn$180.5bn$195.3bn$247.1bn$274.9bn
Net income——$5.2bn$3.4bn$6.0bn
Stock-based pay$268.0m$264.0m$286.0m$308.0m$291.0m
Buybacks$7.7bn$7.6bn$2.3bn$7.0bn$3.6bn
Dividends$1.3bn$1.4bn$1.4bn$1.6bn$1.6bn
Diluted shares341m313m297m283m269m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.